61.84
price up icon0.65%   0.40
after-market アフターアワーズ: 61.84
loading
前日終値:
$61.44
開ける:
$60.6
24時間の取引高:
485.97K
Relative Volume:
0.67
時価総額:
$4.42B
収益:
$58.89M
当期純損益:
$-240.88M
株価収益率:
-19.95
EPS:
-3.1
ネットキャッシュフロー:
$-239.96M
1週間 パフォーマンス:
+5.60%
1か月 パフォーマンス:
+9.26%
6か月 パフォーマンス:
+80.45%
1年 パフォーマンス:
+33.94%
1日の値動き範囲:
Value
$59.84
$62.24
1週間の範囲:
Value
$58.75
$62.24
52週間の値動き範囲:
Value
$19.45
$63.96

Kymera Therapeutics Inc Stock (KYMR) Company Profile

Name
名前
Kymera Therapeutics Inc
Name
セクター
Healthcare (1135)
Name
電話
857-285-5314
Name
住所
500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN
Name
職員
218
Name
Twitter
Name
次回の収益日
2025-08-01
Name
最新のSEC提出書
Name
KYMR's Discussions on Twitter

KYMR を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
KYMR
Kymera Therapeutics Inc
61.84 4.39B 58.89M -240.88M -239.96M -3.10
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
425.57 107.66B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
651.80 68.74B 14.25B 4.58B 3.88B 41.77
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
456.04 58.93B 2.46B -319.09M -52.09M -2.4669
Biotechnology icon
ARGX
Argen X Se Adr
818.50 50.51B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
INSM
Insmed Inc
189.60 41.29B 398.11M -1.03B -868.57M -5.7032

Kymera Therapeutics Inc Stock (KYMR) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-10-24 繰り返されました B. Riley Securities Buy
2025-10-21 開始されました Mizuho Outperform
2025-09-18 繰り返されました H.C. Wainwright Buy
2025-09-17 開始されました Barclays Overweight
2025-09-16 開始されました RBC Capital Mkts Outperform
2025-07-30 再開されました B. Riley Securities Buy
2025-07-03 再開されました Morgan Stanley Overweight
2025-06-03 アップグレード B. Riley Securities Neutral → Buy
2025-06-03 アップグレード Morgan Stanley Equal-Weight → Overweight
2025-06-02 アップグレード BofA Securities Neutral → Buy
2025-05-20 再開されました Stifel Buy
2025-03-13 開始されました Citigroup Buy
2024-12-10 開始されました BTIG Research Buy
2024-12-06 開始されました BMO Capital Markets Market Perform
2024-12-02 アップグレード Wells Fargo Equal Weight → Overweight
2024-11-18 開始されました Stephens Overweight
2024-09-09 再開されました Leerink Partners Outperform
2024-08-26 アップグレード Wolfe Research Peer Perform → Outperform
2024-04-22 開始されました Oppenheimer Outperform
2024-02-15 開始されました Wolfe Research Peer Perform
2024-01-04 アップグレード JP Morgan Neutral → Overweight
2024-01-03 ダウングレード BofA Securities Buy → Neutral
2023-12-19 ダウングレード Wells Fargo Overweight → Equal Weight
2023-06-30 開始されました Truist Buy
2023-05-05 アップグレード Raymond James Mkt Perform → Outperform
2022-12-06 ダウングレード Credit Suisse Outperform → Neutral
2022-11-08 開始されました Raymond James Mkt Perform
2022-08-15 開始されました Jefferies Buy
2022-08-03 開始されました Goldman Buy
2022-07-20 開始されました SVB Leerink Mkt Perform
2022-04-28 開始されました Credit Suisse Outperform
2022-03-10 開始されました JP Morgan Neutral
2022-02-10 開始されました Wells Fargo Overweight
2021-09-30 開始されました B. Riley Securities Neutral
2021-09-30 開始されました Stifel Buy
2021-09-10 ダウングレード BofA Securities Buy → Neutral
2021-05-21 開始されました UBS Buy
2021-04-14 開始されました Berenberg Buy
2020-12-04 開始されました H.C. Wainwright Buy
2020-09-15 開始されました BofA Securities Neutral
2020-09-15 開始されました Cowen Outperform
2020-09-15 開始されました Guggenheim Buy
2020-09-15 開始されました Morgan Stanley Equal-Weight
すべてを表示

Kymera Therapeutics Inc (KYMR) 最新ニュース

pulisher
Oct 31, 2025

Kymera Therapeutics Inc expected to post a loss of 81 cents a shareEarnings Preview - TradingView

Oct 31, 2025
pulisher
Oct 31, 2025

Pattern recognition hints at Kymera Therapeutics Inc. upsidePortfolio Performance Summary & Stepwise Swing Trade Plans - newser.com

Oct 31, 2025
pulisher
Oct 30, 2025

Kymera Therapeutics (NASDAQ:KYMR) CEO Sells $1,829,700.00 in Stock - MarketBeat

Oct 30, 2025
pulisher
Oct 30, 2025

Is Kymera Therapeutics Inc. stock supported by innovation pipelineJuly 2025 Pullbacks & Verified Chart Pattern Signals - newser.com

Oct 30, 2025
pulisher
Oct 30, 2025

Is Kymera Therapeutics Inc. stock attractive for ETFsTrade Exit Summary & Community Consensus Trade Signals - newser.com

Oct 30, 2025
pulisher
Oct 30, 2025

How hedge fund analytics apply to Kymera Therapeutics Inc. stockJuly 2025 Momentum & Accurate Trade Setup Notifications - newser.com

Oct 30, 2025
pulisher
Oct 29, 2025

Is Kymera Therapeutics Inc. meeting your algorithmic filter criteriaJuly 2025 Pullbacks & AI Forecasted Entry and Exit Points - newser.com

Oct 29, 2025
pulisher
Oct 29, 2025

Kymera Therapeutics Insider Sold Shares Worth $1,829,737, According to a Recent SEC Filing - MarketScreener

Oct 29, 2025
pulisher
Oct 29, 2025

KYMR insider trade: CEO option exercise and matching share sales - Stock Titan

Oct 29, 2025
pulisher
Oct 29, 2025

What valuation multiples suggest for Kymera Therapeutics Inc. stockJuly 2025 Analyst Calls & Technical Entry and Exit Alerts - newser.com

Oct 29, 2025
pulisher
Oct 29, 2025

How to read the order book for Kymera Therapeutics Inc.July 2025 Patterns & Safe Entry Momentum Tips - newser.com

Oct 29, 2025
pulisher
Oct 29, 2025

Kymera Therapeutics (KYMR): Assessing Valuation Following Promising Preclinical Data for KT-579 in Autoimmune Diseases - Yahoo Finance

Oct 29, 2025
pulisher
Oct 28, 2025

How Investors Are Reacting To Kymera Therapeutics (KYMR) Preclinical Data on Oral IRF5 Degrader in Lupus and RA - Yahoo Finance

Oct 28, 2025
pulisher
Oct 28, 2025

Is Kymera Therapeutics Inc. stock undervalued vs historical averagesJuly 2025 Earnings & Low Volatility Stock Recommendations - Fundação Cultural do Pará

Oct 28, 2025
pulisher
Oct 28, 2025

How analysts rate Kymera Therapeutics Inc. stock todayJuly 2025 Patterns & Real-Time Volume Trigger Notifications - newser.com

Oct 28, 2025
pulisher
Oct 28, 2025

Kymera Therapeutics to Report Third Quarter 2025 Financial Results on November 4, 2025 - The Manila Times

Oct 28, 2025
pulisher
Oct 28, 2025

Kymera Therapeutics to Announce Q3 2025 Financial Results and Host Video Conference on November 4, 2025 - Quiver Quantitative

Oct 28, 2025
pulisher
Oct 28, 2025

Kymera Therapeutics to Report Third Quarter 2025 Financial Results on November 4, 2025 - GlobeNewswire Inc.

Oct 28, 2025
pulisher
Oct 28, 2025

What technical charts say about Kymera Therapeutics Inc. stockJuly 2025 Summary & Community Verified Trade Signals - Fundação Cultural do Pará

Oct 28, 2025
pulisher
Oct 27, 2025

Earnings Recap: Why Kymera Therapeutics Inc. stock could outperform in 2025Trend Reversal & Free Expert Approved Momentum Trade Ideas - Fundação Cultural do Pará

Oct 27, 2025
pulisher
Oct 27, 2025

Why Kymera Therapeutics Inc. stock could outperform in 2025July 2025 Big Picture & Real-Time Stock Entry Alerts - Fundação Cultural do Pará

Oct 27, 2025
pulisher
Oct 27, 2025

Kymera Therapeutics Advances KT-621 Study for Atopic Dermatitis - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Kymera’s IRF5 degrader shows promise in preclinical lupus, RA studies - Investing.com

Oct 27, 2025
pulisher
Oct 27, 2025

Kymera Therapeutics Presents New Preclinical Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at the American College of Rheumatology Annual Meeting - Investing News Network

Oct 27, 2025
pulisher
Oct 27, 2025

Kymera (NASDAQ: KYMR) shows KT-579 IRF5 degrader activity in lupus, RA at ACR - Stock Titan

Oct 27, 2025
pulisher
Oct 25, 2025

Kymera added to Citi catalyst watch list on atopic dermatitis asset data readout - MSN

Oct 25, 2025
pulisher
Oct 24, 2025

Kymera Therapeutics (KYMR) Awaits Key Phase 1b Data Release - GuruFocus

Oct 24, 2025
pulisher
Oct 24, 2025

Kymera added to Citi catalyst watch list on atopic dermatitis asset data readout (KYMR:NASDAQ) - Seeking Alpha

Oct 24, 2025
pulisher
Oct 24, 2025

B. Riley Boosts Price Target on Kymera Therapeutics to $80 From $60, Keeps Buy Rating - MarketScreener

Oct 24, 2025
pulisher
Oct 24, 2025

B. Riley Issues Positive Forecast for Kymera Therapeutics (NASDAQ:KYMR) Stock Price - MarketBeat

Oct 24, 2025
pulisher
Oct 24, 2025

Kymera Therapeutics (KYMR) Gains Attention with Upcoming Data Re - GuruFocus

Oct 24, 2025
pulisher
Oct 23, 2025

Kymera Therapeutics, Inc. (KYMR) May Report Negative Earnings: Know the Trend Ahead of Q3 Release - sharewise.com

Oct 23, 2025
pulisher
Oct 23, 2025

What drives Kymera Therapeutics Inc stock priceTrade Execution Strategies & Exceptional Capital Trading - earlytimes.in

Oct 23, 2025
pulisher
Oct 23, 2025

Kymera Therapeutics (NASDAQ:KYMR) Upgraded by Mizuho to "Strong-Buy" Rating - MarketBeat

Oct 23, 2025
pulisher
Oct 22, 2025

Kymera Therapeutics, Inc.Common Stock (NQ: KYMR - FinancialContent

Oct 22, 2025
pulisher
Oct 22, 2025

BTIG Maintains 'Buy' Rating on KYMR, Raises Price Target to $75 - GuruFocus

Oct 22, 2025
pulisher
Oct 22, 2025

BTIG Maintains Kymera Therapeutics (KYMR) Buy Recommendation - Nasdaq

Oct 22, 2025
pulisher
Oct 21, 2025

Is Kymera Therapeutics Inc a good long term investmentHigh Dividend Yield Stocks & Free Expert Stock Watchlists - earlytimes.in

Oct 21, 2025

Kymera Therapeutics Inc (KYMR) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$37.54
price up icon 1.62%
$93.48
price up icon 0.96%
$28.61
price down icon 0.21%
$103.91
price down icon 0.73%
biotechnology ONC
$310.48
price up icon 0.73%
$189.60
price down icon 2.38%
大文字化:     |  ボリューム (24 時間):